Compare · CLYM vs NVO
CLYM vs NVO
Side-by-side comparison of Climb Bio Inc. (CLYM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLYM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 277.1x CLYM ($626.6M).
- Over the past year, CLYM is up 410.1% and NVO is down 28.6% - CLYM leads by 438.7 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 2 for CLYM).
- NVO has more recent analyst coverage (25 ratings vs 15 for CLYM).
- Company
- Climb Bio Inc.
- Novo Nordisk A/S
- Price
- $9.82-10.07%
- $38.82-1.05%
- Market cap
- $626.6M
- $173.66B
- 1M return
- -30.16%
- -10.14%
- 1Y return
- +410.13%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 4
- Recent ratings
- 15
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CLYM
- Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
- Director Ra Capital Management, L.P. exercised 70,000 shares at a strike of $2.79 (SEC Form 4)
- Director Thomas Stephen Basil sold $1,366,820 worth of shares (100,000 units at $13.67) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 467,969 units (SEC Form 4)
- Climb Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
- Climb Bio to Present at Upcoming Investor Conferences
- SEC Form 8-K filed by Climb Bio Inc.
- SEC Form 10-Q filed by Climb Bio Inc.
- Climb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank